Plain-English translation of NCT07444814 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new cancer treatment called , which is designed to target and kill cancer cells in advanced solid tumors. The study will first test increasing doses of the medication in a small group of patients to find the safest dose, and then expand to test that dose in a larger group. The goal is to understand how well and how safely this new treatment works.
Many people with advanced lung, ovarian, and endometrial cancers run out of effective treatment options. This medication targets a specific protein found on cancer cells, offering a potentially new way to fight these cancers that may help when other treatments no longer work.
You likely qualify if…
You likely don't qualify if…
You will receive the medication as an intravenous infusion (through a vein) every three weeks in 21-day treatment cycles. The trial has two phases: first, doctors will gradually increase the dose in a small group to find the safest level, and then expand to give that dose to more patients. You will have regular visits for blood tests, imaging scans, and check-ins to monitor how you are responding and any side effects you may experience.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States